AR052830A1 - Regimen de cladribina para tratar esclerosis multiple - Google Patents

Regimen de cladribina para tratar esclerosis multiple

Info

Publication number
AR052830A1
AR052830A1 ARP050105411A ARP050105411A AR052830A1 AR 052830 A1 AR052830 A1 AR 052830A1 AR P050105411 A ARP050105411 A AR P050105411A AR P050105411 A ARP050105411 A AR P050105411A AR 052830 A1 AR052830 A1 AR 052830A1
Authority
AR
Argentina
Prior art keywords
multiple sclerosis
cladribine
regime
treat multiple
preparation
Prior art date
Application number
ARP050105411A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR052830A1 publication Critical patent/AR052830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de Cladribina para la preparacion de una formulacion farmacéutica para el tratamiento de la esclerosis multiple, especialmente la esclerosis multiple recidiva-remision o la esclerosis multiple progresiva precoz secundaria, en la que la preparacion es para ser administrada oralmente y en la que los tratamientos repetidos son posibles.
ARP050105411A 2004-12-22 2005-12-21 Regimen de cladribina para tratar esclerosis multiple AR052830A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
AR052830A1 true AR052830A1 (es) 2007-04-04

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105411A AR052830A1 (es) 2004-12-22 2005-12-21 Regimen de cladribina para tratar esclerosis multiple

Country Status (24)

Country Link
US (2) US7713947B2 (es)
EP (6) EP2805723B1 (es)
JP (7) JP5795456B2 (es)
KR (1) KR20070091662A (es)
AR (1) AR052830A1 (es)
AU (2) AU2005318190B2 (es)
BR (1) BRPI0517132B8 (es)
CA (2) CA2588966C (es)
CY (3) CY1112614T1 (es)
DK (2) DK3332789T3 (es)
EA (1) EA015799B1 (es)
ES (1) ES2921858T3 (es)
FR (1) FR18C1008I2 (es)
HR (1) HRP20120228T1 (es)
HU (2) HUE059133T2 (es)
IL (2) IL183930A0 (es)
LT (2) LT3332789T (es)
LU (1) LUC00064I2 (es)
MX (1) MX2007007610A (es)
NO (1) NO20073813L (es)
PL (3) PL1827461T3 (es)
SG (1) SG160391A1 (es)
SI (2) SI2805723T1 (es)
WO (1) WO2006067141A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925151B2 (en) * 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CN111356460A (zh) * 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (en) 2002-09-25 2013-05-01 Brigham Young University Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
PT1608344E (pt) * 2003-03-28 2010-09-02 Ares Trading Sa Formulações orais de cladribina
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
US9925151B2 (en) * 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
PL2805723T3 (pl) 2018-04-30
LTPA2018503I1 (lt) 2018-03-12
LUC00064I2 (es) 2018-03-28
EP3332789B1 (en) 2022-04-06
CA2588966C (en) 2020-07-21
SI3332789T1 (sl) 2022-08-31
JP6430554B2 (ja) 2018-11-28
JP5908863B2 (ja) 2016-04-26
JP2016138128A (ja) 2016-08-04
DK2805723T3 (da) 2018-01-29
JP2017101061A (ja) 2017-06-08
KR20070091662A (ko) 2007-09-11
US8377903B2 (en) 2013-02-19
EP2275110B1 (en) 2013-07-10
EP2805723A1 (en) 2014-11-26
EA200701221A1 (ru) 2008-02-28
WO2006067141A1 (en) 2006-06-29
EP1827461A1 (en) 2007-09-05
SI2805723T1 (en) 2018-02-28
IL183930A0 (en) 2007-10-31
AU2005318190A1 (en) 2006-06-29
CA3087419A1 (en) 2006-06-29
ES2921858T3 (es) 2022-09-01
LTC2805723I2 (lt) 2022-04-25
EP2275110A2 (en) 2011-01-19
JP5795456B2 (ja) 2015-10-14
EP2263678B1 (en) 2014-06-11
NO20073813L (no) 2007-09-21
EP2263678A2 (en) 2010-12-22
EP2263678A3 (en) 2011-04-27
CA3087419C (en) 2023-03-07
FR18C1008I2 (fr) 2019-03-01
SG160391A1 (en) 2010-04-29
JP6092945B2 (ja) 2017-03-08
US20090081163A1 (en) 2009-03-26
BRPI0517132A (pt) 2008-09-30
EP3332789A1 (en) 2018-06-13
JP2008524313A (ja) 2008-07-10
BRPI0517132B8 (pt) 2021-05-25
HUS1800009I1 (hu) 2018-05-02
CA2588966A1 (en) 2006-06-29
PL3332789T3 (pl) 2022-08-22
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
HUE059133T2 (hu) 2022-10-28
LUC00064I1 (es) 2018-02-14
CY2018006I2 (el) 2018-06-27
BRPI0517132B1 (pt) 2020-02-18
IL212421A (en) 2014-01-30
CY1112614T1 (el) 2016-02-10
JP2013216664A (ja) 2013-10-24
EA015799B1 (ru) 2011-12-30
EP2805723B1 (en) 2018-01-17
CY2018006I1 (el) 2018-06-27
DK3332789T3 (da) 2022-07-11
EP1827461B1 (en) 2012-02-29
LT3332789T (lt) 2022-07-25
HRP20120228T1 (hr) 2012-04-30
CY1119790T1 (el) 2018-06-27
EP4070800A1 (en) 2022-10-12
FR18C1008I1 (es) 2018-03-30
EP2275110A3 (en) 2011-04-27
US7713947B2 (en) 2010-05-11
AU2011200768A1 (en) 2011-03-17
JP2018165271A (ja) 2018-10-25
JP2015180685A (ja) 2015-10-15
MX2007007610A (es) 2007-08-03
JP6290962B2 (ja) 2018-03-07
IL212421A0 (en) 2011-06-30
AU2011200768B2 (en) 2012-09-13
US20100203017A1 (en) 2010-08-12
AU2005318190B2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR067347A1 (es) Combinacion antihelmintica
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
AR044039A1 (es) Combinaciones antineoplasicas
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR073435A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
RU2008148597A (ru) Фармацевтические комбинации
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
CO6470875A2 (es) Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares
RU2012129839A (ru) Комбинация теобромина с деконгестантом и ее применение для лечения кашля
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR063819A1 (es) Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos.
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
AR108792A1 (es) Composiciones que comprenden timolol
CL2008002485A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos.

Legal Events

Date Code Title Description
FC Refusal